2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.06G.04 Clinicopathological Differences between EGFR Mutated and EGFR Wild-Type Lung Adenocarcinoma with Papillary Predominant Pattern

EP.06G.04 Clinicopathological Differences between EGFR Mutated and EGFR Wild-Type Lung Adenocarcinoma with Papillary Predominant Pattern

Back to course

Pdf Summary

This study examines the clinicopathological differences between epidermal growth factor receptor (EGFR)-mutated and wild-type (WT) lung adenocarcinoma (LUAD), focusing on papillary predominant adenocarcinoma (PPA). The research involved two primary cohorts: Cohort 1 comprised 722 consecutive stage I LUAD patients categorized by predominant subtype, where 352 had EGFR mutations and 370 were WT. Cohort 2 utilized data from the Cancer Genome Atlas Program (TCGA) to analyze gene expression differences between the two groups.<br /><br />Key findings from the study indicate that PPA with EGFR mutation exhibits a significantly worse 5-year recurrence-free survival (RFS) rate compared to WT (70.6% vs. 83.3%, p=0.02). Interestingly, EGFR-mutated PPAs displayed a smaller invasive size and less frequent vessel invasion than WT; however, the recurrence rate was notably higher. Despite these observations, TCGA cohort analysis did not reveal significant differences in cancer cells or tumor microenvironment (TME) between the EGFR-mutated and WT groups.<br /><br />The study places particular focus on the expression levels of galectin-1 and galectin-3, proteins associated with tumor metastasis and resistance to anoikis. While LGALS3 (encoding galectin-3) tended to display higher scores in EGFR-mutated tumors, significant expression was only confirmed for galectin-3 through immunochemical evaluation, showing markedly higher expression in EGFR-mutant PPAs than WTs (p=0.01). <br /><br />Overall, the research highlights significant prognostic differences between EGFR-mutated and WT PPAs in pathological stage I LUADs, with a specific focus on biological markers like galectin-3 that could inform future therapeutic strategies.

Asset Subtitle

Eisuke Goto

Meta Tag

Speaker Eisuke Goto

Topic Pathology and Biomarkers

Keywords

EGFR-mutated lung adenocarcinoma

wild-type lung adenocarcinoma

papillary predominant adenocarcinoma

Cancer Genome Atlas Program

recurrence-free survival

galectin-3 expression

tumor microenvironment

gene expression differences

prognostic differences

therapeutic strategies